反応式
[CH:1]1([NH:6][C:7]2[N:12]3[N:13]=[C:14]([C:23]4[CH:28]=[CH:27][C:26]([F:29])=[CH:25][CH:24]=4)[C:15]([C:16](=O)[CH:17]=[CH:18]N(C)C)=[C:11]3[CH:10]=[CH:9][N:8]=2)[CH2:5][CH2:4][CH2:3][CH2:2]1.[CH2:30]([NH:34][C:35]([NH2:37])=[NH:36])[CH2:31][CH2:32][CH3:33]>>[CH2:30]([NH:34][C:35]1[N:37]=[C:16]([C:15]2[C:14]([C:23]3[CH:24]=[CH:25][C:26]([F:29])=[CH:27][CH:28]=3)=[N:13][N:12]3[C:11]=2[CH:10]=[CH:9][N:8]=[C:7]3[NH:6][CH:1]2[CH2:2][CH2:3][CH2:4][CH2:5]2)[CH:17]=[CH:18][N:36]=1)[CH2:31][CH2:32][CH3:33]参加物
3
実験手順
In a similar manner as described in Example 1 above, 3-[2-(butylamino)pyrimidin-4-yl]-N-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-7-amine (80 mg, 72%) was prepared from 1-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-3-(dimethylamino)prop-2-en-1-one and N-butylguanidine. 1H NMR (CDCl3): δ 8.04 (d, 1H), 7.74 (d, 1H), 7.60 (dd, 2H), 7.48 (d, 1H), 7.13 (t, 2H), 6.36 (d, 1H), 6.25 (d, 1H), 5.05 (t, 1H), 4.51 (m, 1H), 3.42 (qt, 2H), 2.16 (m, 2H), 1.78 (m, 2H), 1.56–1.70 (m, 6H), 1.43 (m, 2H), 0.95 (t, 3H). MS m/z 446 (M+1).
出典と根拠
- ORDレコード
- ord-702dfb664d224c438de1202a63cbbd5d
- 出典データセット
- uspto-grants-2007_07
- 特許番号
- US07247626B2
関連ノート
読み込み中…